170 related articles for article (PubMed ID: 36167542)
21. METTL3 promotes lung adenocarcinoma tumor growth and inhibits ferroptosis by stabilizing SLC7A11 m
Xu Y; Lv D; Yan C; Su H; Zhang X; Shi Y; Ying K
Cancer Cell Int; 2022 Jan; 22(1):11. PubMed ID: 34996469
[TBL] [Abstract][Full Text] [Related]
22. Anlotinib Suppresses Oral Squamous Cell Carcinoma Growth and Metastasis by Targeting the RAS Protein to Inhibit the PI3K/Akt Signalling Pathway.
Lu Y; Lin J; Duan M; Rui Y; Zheng H; Zhu L; Zhu X; Wei J
Anal Cell Pathol (Amst); 2021; 2021():5228713. PubMed ID: 34926131
[TBL] [Abstract][Full Text] [Related]
23. RNA N6-Methyladenosine (m6A) Methyltransferase-like 3 Facilitates Tumorigenesis and Cisplatin Resistance of Arecoline-Exposed Oral Carcinoma.
Wang C; Kadigamuwa C; Wu S; Gao Y; Chen W; Gu Y; Wang S; Li X
Cells; 2022 Nov; 11(22):. PubMed ID: 36429032
[TBL] [Abstract][Full Text] [Related]
24. New insights on the interaction between m
Shen G; Li F; Wang Y; Huang Y; Aizezi G; Yuan J; Ma C; Lin C
World J Surg Oncol; 2023 Jan; 21(1):25. PubMed ID: 36710350
[TBL] [Abstract][Full Text] [Related]
25. Metabolic reprogramming driven by METTL1-mediated tRNA m7G modification promotes acquired anlotinib resistance in oral squamous cell carcinoma.
Chen J; Zhou Q; Li S; Ling R; Zhao Y; Chen D; Wang A; Cao Y
Transl Res; 2024 Jun; 268():28-39. PubMed ID: 38280546
[TBL] [Abstract][Full Text] [Related]
26. METTL3 modulates m6A modification of CDC25B and promotes head and neck squamous cell carcinoma malignant progression.
Guo YQ; Wang Q; Wang JG; Gu YJ; Song PP; Wang SY; Qian XY; Gao X
Exp Hematol Oncol; 2022 Mar; 11(1):14. PubMed ID: 35287752
[TBL] [Abstract][Full Text] [Related]
27. N6-Methyladenosine Modification of CIRCKRT17 Initiated by METTL3 Promotes Osimertinib Resistance of Lung Adenocarcinoma by EIF4A3 to Enhance YAP1 Stability.
Ji Y; Zhao Q; Feng W; Peng Y; Hu B; Chen Q
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428672
[TBL] [Abstract][Full Text] [Related]
28. METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N
Wan W; Ao X; Chen Q; Yu Y; Ao L; Xing W; Guo W; Wu X; Pu C; Hu X; Li Z; Yao M; Luo D; Xu X
Mol Cancer; 2022 Feb; 21(1):60. PubMed ID: 35197058
[TBL] [Abstract][Full Text] [Related]
29. METTL3/m
Ge F; Li Z; Hu J; Pu Y; Zhao F; Kong L
Front Pharmacol; 2022; 13():1002565. PubMed ID: 36386128
[TBL] [Abstract][Full Text] [Related]
30. METTL3 promotes prostate cancer progression by regulating miR-182 maturation in m6A-dependent manner.
Wang D; Wang X; Huang B; Zhao Y; Tu W; Jin X; Shao Y; Zhu Y; Lu G
Andrologia; 2022 Aug; 54(7):1581-1591. PubMed ID: 35413135
[TBL] [Abstract][Full Text] [Related]
31. Long noncoding RNA lnc-H2AFV-1 promotes cell growth by regulating aberrant m6A RNA modification in head and neck squamous cell carcinoma.
Chen X; Liu Y; Sun D; Sun R; Wang X; Li M; Song N; Ying J; Guo T; Jiang Y
Cancer Sci; 2022 Jun; 113(6):2071-2084. PubMed ID: 35403343
[TBL] [Abstract][Full Text] [Related]
32. FTO suppresses glycolysis and growth of papillary thyroid cancer via decreasing stability of APOE mRNA in an N6-methyladenosine-dependent manner.
Huang J; Sun W; Wang Z; Lv C; Zhang T; Zhang D; Dong W; Shao L; He L; Ji X; Zhang P; Zhang H
J Exp Clin Cancer Res; 2022 Jan; 41(1):42. PubMed ID: 35090515
[TBL] [Abstract][Full Text] [Related]
33. The m6A methyltransferase METTL3 regulates autophagy and sensitivity to cisplatin by targeting ATG5 in seminoma.
Chen H; Xiang Y; Yin Y; Peng J; Peng D; Li D; Kitazawa R; Tang Y; Yang J
Transl Androl Urol; 2021 Apr; 10(4):1711-1722. PubMed ID: 33968659
[TBL] [Abstract][Full Text] [Related]
34. RNA m
Lin Z; Niu Y; Wan A; Chen D; Liang H; Chen X; Sun L; Zhan S; Chen L; Cheng C; Zhang X; Bu X; He W; Wan G
EMBO J; 2020 Jun; 39(12):e103181. PubMed ID: 32368828
[TBL] [Abstract][Full Text] [Related]
35. METTL3 mediated m
Zhou R; Gao Y; Lv D; Wang C; Wang D; Li Q
Biochem Biophys Res Commun; 2019 Jul; 515(2):310-317. PubMed ID: 31153635
[TBL] [Abstract][Full Text] [Related]
36. Anlotinib exerts potent antileukemic activities in Ph chromosome negative and positive B-cell acute lymphoblastic leukemia via perturbation of PI3K/AKT/mTOR pathway.
Chen Q; Lai Q; Jiang Y; Yao J; Chen Q; Zhang L; Wang C; Zhou Y; Deng M; Xu B
Transl Oncol; 2022 Nov; 25():101516. PubMed ID: 35985203
[TBL] [Abstract][Full Text] [Related]
37. N6-methyladenosine methyltransferase METTL3 promotes colorectal cancer cell proliferation through enhancing MYC expression.
Xiang S; Liang X; Yin S; Liu J; Xiang Z
Am J Transl Res; 2020; 12(5):1789-1806. PubMed ID: 32509177
[TBL] [Abstract][Full Text] [Related]
38. Overexpression of methyltransferase-like 3 and 14 in oral squamous cell carcinoma.
Wu S; Makeudom A; Sun X; Li X; Xu D; Sastraruji T; Lumbikananda N; Buranaphatthana W; Krisanaprakornkit S
J Oral Pathol Med; 2022 Feb; 51(2):134-145. PubMed ID: 34689367
[TBL] [Abstract][Full Text] [Related]
39. The N6-methyladenosine modification enhances ferroptosis resistance through inhibiting SLC7A11 mRNA deadenylation in hepatoblastoma.
Liu L; He J; Sun G; Huang N; Bian Z; Xu C; Zhang Y; Cui Z; Xu W; Sun F; Zhuang C; Man Q; Gu S
Clin Transl Med; 2022 May; 12(5):e778. PubMed ID: 35522946
[TBL] [Abstract][Full Text] [Related]
40. N6-Methyladenosine Methyltransferase METTL3 Promotes Angiogenesis and Atherosclerosis by Upregulating the JAK2/STAT3 Pathway via m6A Reader IGF2BP1.
Dong G; Yu J; Shan G; Su L; Yu N; Yang S
Front Cell Dev Biol; 2021; 9():731810. PubMed ID: 34950654
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
